In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia Cavazzoni, M.D., stepped down in January and joined Pfizer's C-suite as chief medical officer.

Pfizer is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach for the drug giant. The company said Monday the stoppage comes after it reviewed clinical data and a study subject developed a liver injury that might have been caused by the drug,

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from a phase 3 trial by Eli Lilly.